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Abstract
Increases in susceptible patient populations and advances in identification methods have resulted 
in the continued recognition of novel yeasts as agents of human infection. Most of these agents are 
members of the well-recognized genera Candida, Cryptococcus, Trichosporon, and Rhodotorula. 
Some of these agents are “cryptic species,” members of species complexes, and may not be 
detectable using classical carbohydrate assimilation-based methods of yeast identification. Such 
species require DNA- or MALDI-based methods for correct identification, although sporadic 
isolates may not routinely require delineation to the individual species level. The coming end of 
the fungal taxonomy rules requiring separate names for sexual and asexual forms of the same 
fungus will hopefully allow greater clarity, as names for medically important yeast can now be 
based on the needs of the medical mycology community and the common goal of better 
communication between laboratory and clinician.
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Introduction
Recent developments in medical mycology have revolutionized the detection, identification 
and treatment of fungal infections. The proven utility of DNA sequencing has enabled the 
identification of fungal organisms even when present in formalin-fixed tissue sections, 
growing poorly, not sporulating, not viable, or otherwise present in less than optimal 
conditions. MALDI-TOF mass spectrometry [1] and Fourier Transform Infrared 
spectroscopy (FT-IR) based identification systems are beginning to demonstrate similar 
levels of sensitivity and specificity with yeasts and some molds. The ability to identify a 
broader range of fungal isolates and understand their taxonomic placement has allowed 
targeting of antifungal drugs to specific genera or groups of organisms. Furthermore, the 
growing use of whole-genome sequencing of clinically important fungal organisms is 
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allowing specific antifungal resistance targets and virulence factors to be described and 
analyzed in greater detail than before. The overall effects of this research are to predict with 
greater specificity and accuracy the particular antifungal drugs that would be most useful in 
treating a particular organism and to identify rapidly those isolates likely to be resistant to 
various drugs.
The ability to identify organisms based on DNA sequences has contributed to the 
recognition of “cryptic species” or “species complexes.” These are groups of organisms that 
are indistinguishable from one another when morphologic or biochemical traits are used for 
identification, but have distinct DNA sequences at particular target regions that can be used 
to separate them. Several “cryptic species” have also been recognized as human pathogens, 
albeit at lower prevalence than their original counterparts. In many cases, the cryptic species 
have been given formal species names, such as Candida orthopsilosis and C. metapsilosis 
within the Candida parapsilosis species complex. These findings have led to re-evaluating 
the definition of a “species,” and we currently use a phylogenetic definition based on the 
degree of sequence identity (homology) between an unknown isolate and its comparators at 
particular genetic loci [2••, 3]. However, there are still no hard and fast rules for the degree 
of concordance necessary for two isolates to be considered “identical” or “different” species 
[4•].
Another recent taxonomic change that will soon impact the medical mycology community is 
the end of “one fungus-two names,” the long-established taxonomic rule of requiring 
separate names to be used for the sexual and asexual forms of a fungus [5••]. For example, 
the asexual name Candida kefyr and the sexual name Kluyveromyces marxianus refer to the 
same organism. This practice has caused confusion in the clinical mycology community for 
decades, due to difficulty in recognizing that both names describe a single organism. The 
use of DNA-based phylogenetic methods means that an organism can be named and placed 
in a taxonomic grouping without having to establish the presence of sexual spores and 
spore-bearing structures, which had been a prerequisite for assigning a sexual name. For this 
reason, the “two-name” system rapidly became obsolete, and on July 30, 2011, the XVIII 
International Botanical Congress decided to end this practice. Although the International 
Botanical Congress is still formulating rules for the new nomenclature, it appears that the 
correct name will be the earliest name published according to the rules of legitimacy, and 
organisms previously designated with two names should have the earliest name considered 
legitimate and valid. This suggests that in cases when adoption of a sexual (teleomorph) 
name will cause confusion, asexual (anamorph) names that are well known and commonly 
used will be adopted and validated. Although it is not clear what will happen to the less 
common name, this is a very welcome development, as it promotes clear communication 
between the laboratory and the clinician and allows teaching of one name for each organism. 
In some cases input will be required from the clinical mycology community to determine the 
name to be retained.
The purpose of this paper is to review each major genus of medically important yeast from 
the perspective of recent taxonomic changes and their clinical impacts. This paper will use 
the commonly accepted names, which are usually the anamorph names, although the 
teleomorph names will be referred to as appropriate.
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Candida and Other Ascomycetous Yeast
This genus contains approximately 200 species, and is the largest genus of medically 
important yeast. At least 30 Candida species have been recognized as causes of human 
infection, and the list continues to expand [6].
Candida albicans
Candida albicans remains the major pathogen in this group, although its prevalence in blood 
cultures is being surpassed by the group of non-albicans species. A general-purpose 
genotype (GPG; also known as clade 1) of C. albicans has been identified and has been 
reported to cause more infections than other C. albicans genotypes. A recent French study 
suggests that GPG bloodstream strains have a higher prevalence in younger patients 
(exceeding 40 % in infants less than one year), and may be more virulent than other strains 
in younger patients [7].
Candida dubliniensis
Candida dubliniensis is a closely related organism that has many phenotypic similarities to 
C. albicans. Both species display a green color on ChromAgar media, produce germ tubes 
when incubated with serum, and produce chlamydospores on cornmeal or rice-Tween agars. 
Pal’s (sunflower seed), tobacco, and Niger seed agars have been proposed as methods to 
distinguish the two species. However none of these phenotypic methods used alone is 
completely reliable in separating them. In a recent College of American Pathologists 
proficiency sample (2010-A-F01), 411 (39.4 %) of 1046 participant laboratories correctly 
identified the challenge isolate as C. dubliniensis, while 445 participants (42.6 %) identified 
the isolate incorrectly as C. albicans (CAP final critique F-A survey 2010, College of 
American Pathologists). The 13 laboratories that used molecular methods all provided the 
correct identification. The most reliable methods to separate these two species at this time 
are molecular-based (DNA sequencing, specific DNA probe, MALDI-TOF) [8].
The question of whether it is necessary to separate these two species routinely in the clinical 
laboratory has recently been addressed [9]. Concern has been expressed that C. dubliniensis 
needs to be identified because resistance to fluconazole is frequently seen. Indeed, many of 
the first strains of C. dubliniensis were recovered from oral samples of HIV-infected patients 
who were receiving fluconazole for treatment of mucocutaneous candidiasis, and did exhibit 
elevated MIC values to fluconazole. However, recent investigations of bloodstream and 
other sterile-site isolates collected in surveillance studies showed that very few of these 
isolates demonstrated fluconazole resistance as measured by MIC testing. In a CDC study, 
2/42 (4.7 %) bloodstream isolates had a value of 16 µg/mL, which is considered resistant 
with the new CLSI breakpoints. In the ARTEMIS global surveillance, 3.9 % of 310 isolates 
were resistant to fluconazole. The Denmark national surveillance found 3.1% resistance 
among 65 isolates [9]. Taken together, these studies show that fluconazole resistance among 
C. dubliniensis remains very low, at less than 5 %. These results suggest that speciation may 
be necessary for an outbreak investigation or other epidemiologic purposes, but for most 
sporadic isolates, there is no reason to separate C. dubliniensis from C. albicans routinely. 
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MIC testing will likely provide a more direct answer to the assessment of fluconazole 
resistance in a suspect isolate.
Candida africana
Another organism first described as an atypical Candida albicans is Candida africana, 
which has been reported as a cause of vaginitis in African, German, Spanish and Italian 
patients [reviewed in 10]. The taxonomic position of this organism is still in doubt, and 
many authors consider it as a biovar of C. albicans rather than a distinct species. C. africana 
produces germ tubes in serum but does not produce chlamydospores on corn meal agar. It 
also appears to be susceptible to commonly used antifungal agents. Sequencing of ribosomal 
ITS (internal transcribed spacer) and D1–D2 regions shows a high level of sequence 
homology (>99 %) not sufficient to separate the two taxa. It has been speculated that C. 
africana may have been generated as a result of the parasexual mating cycle reported in C. 
albicans, which can result in extensive genetic recombination between chromosomes and 
the formation of variant genotypes [10].
Candida parapsilosis
DNA-based methods have been used to recognize two additional cryptic species that have 
similar morphology: C. orthopsilosis and C. metapsilosis. C. parapsilosis remains as a major 
opportunistic and nosocomial pathogen that is generally susceptible to antifungal agents, 
although MIC values to echinocandins are elevated. C. metapsilosis and C. orthopsilosis are 
found at low prevalence (~1 %) in most bloodstream isolate collections surveyed [11] and 
respond well to antifungal agents, so routine identification of these species is probably not 
necessary. The three species require molecular methods to distinguish them from one 
another.
Candida glabrata
This species remains one of the most difficult to treat because of its inherent decreased 
susceptibility to azoles and its ability to acquire azole resistance rapidly. It is more closely 
related to Saccharomyces cerevisiae than to other Candida species. The species Candida 
bracarensis and C. nivariensis are genetically related to C. glabrata. Their prevalence in 
clinical samples is low, estimated at 1 % to 2 % of isolates identified phenotypically as C. 
glabrata, but both species have been identified as causative agents of invasive infection. 
Candida bracarensis and C. nivariensis both display white colonies on ChromAgar, in 
contrast to the pink colonies of C. glabrata. They also show variable ability to assimilate 
trehalose, with C. nivariensis unable to assimilate this substrate, C. bracarensis showing 
variable results, and C. glabrata usually able to assimilate trehalose. These three species 
require DNA sequencing to separate them. C. nivariensis is most notable for elevated MIC 
values to azole agents. C. bracarensis is more variable in susceptibility, with both high and 
low azole MIC values reported [12].
Candida tropicalis
Candida tropicalis has been recognized as an increasing cause of bloodstream infection 
outside the United States, particularly in South America and Asia. The reasons for its high 
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prevalence in certain geographic regions of the world are not clear. Although most C. 
tropicalis isolates remain susceptible to antifungals, human isolates with resistance to 
fluconazole are occasionally reported, most recently from Taiwan [13].
Other Non-albicans Candida Species
Candida krusei is the fifth most common cause of candidemia in most surveys. It is well 
known for its innate resistance to fluconazole and reduced susceptibility to amphotericin B. 
The teleomorph has recently been moved from Issatchenkia orientalis to Pichia kudriavzevii 
[14••]. This species is most closely related genetically to Pichia (Candida) norvegensis and 
Candida inconspicua, both rare causes of human infection.
The newly-named genus Meyerozyma includes Candida guilliermondii (Meyerozyma 
guilliermondii) and Candida fermentati (Meyerozyma caribbica). Candida carpophila is 
closely related but with no known teleomorph. The epidemiology of this species complex 
has been recently reviewed [15]; they are agents of bloodstream and deep tissue infections, 
although their incidence is low even among immune-compromised hosts (from 1 % in 
Europe to 3.7 % in Latin America). It is difficult to distinguish accurately among the species 
in this complex and related species such as Candida famata and Candida haemulonii using 
phenotype-based methods due to the great heterogeneity in morphology and carbon 
assimilation profiles. In fact, C. guilliermondii and C. fermentati show no differences on 
standard fermentation and growth tests. Molecular methods are recommended for distinction 
among these species, but such methods may not be needed for identification of sporadic 
isolates.
In some studies, 75 % of C guilliermondii isolates demonstrated reduced susceptibility to 
fluconazole, although most isolates are susceptible to azoles [15]. Along with C. 
parapsilosis, this organism is one of the two yeast species with highest MIC values to 
echinocandin drugs. Most isolates are susceptible to amphotericin B although the species is 
thought to be polyene-tolerant.
Candida palmioleophila is another yeast species commonly misidentified as C. famata or C. 
guilliermondii. It is distinguishable by ITS sequence and MALDI-TOF profile. A recent 
study in Denmark identified 8 isolates of C. palmioleophila, all with high fluconazole MIC 
values, among bloodstream isolates [16]. This species has no known teleomorph.
Candida rugosa has been reported mostly from Latin America as an emerging fungal 
pathogen. Other members of this species complex C. pararugosa and C. pseudorugosa have 
also been described. A recent DNA sequencing analysis of 24 isolates phenotypically 
identified as C. rugosa showed that 10 isolates were actually C. rugosa, while another 10 
isolates were identified as C. pararugosa, 2 isolates were C. pseudorugosa, and two isolates 
with divergent DNA profiles were named as a novel species C. neorugosa [17]. When tested 
using the CLSI broth microdilution method, all classes of antifungal drugs appeared to show 
good activity against these four species [17]. A case of bloodstream infection with a novel 
unnamed species closely related to C. pseudorugosa has also been recently described [18]. 
This organism was reported as resistant to fluconazole and to some echinocandin drugs 
when tested according to the EUCAST microdilution protocol [18].
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Candida kefyr, Candida norvegensis, Candida lusitaniae, Candida zeylanoides and Candida 
famata, among other minor species (see Table 1), cause less than 1 % of bloodstream and 
other deep infections. These species are noteworthy because occasional antifungal resistant 
isolates can be detected, and because commercial yeast identification systems may 
misidentify such isolates in the clinical laboratory. DNA sequencing or MALDI methods are 
required to identify such isolates when definitive information is required. Some of these 
species may not be recognized because they are frequently reported using their teleomorph 
genus names which include Pichia (Candida norvegensis), Lindnera (Candida utilis), 
Clavispora (Candida lusitaniae), Debaryomyces (Candida famata), Kluyveromyces 
(Candida kefyr), Trichomonoascus (Candida ciferrii), Yarrowia (Candida lipolytica), and 
other names that may not be familiar to clinical microbiology personnel (Table 1). Recent 
taxonomic changes compound this problem. For example, the genus Pichia has recently 
been reassessed and the number of assigned species reduced from over 100 to about 20 [19]. 
The species that were removed from this genus were assigned to over 20 other genera. A 
few of these organisms are noteworthy causes of fungal infections. Pichia anomala 
(Candida pelliculosa) was reassigned to the newly created genus Wickerhamomyces as 
Wickerhamomyces anomalus [19]. Earlier the organism Pichia ohmeri (formerly called 
Candida guilliermondii var. membranifaciens) was reassigned to the genus Kodamaea [20]. 
The fungus nomenclature database Mycobank now lists three valid names for this organism: 
Kodamaea ohmeri, Yamadazyma ohmeri, and Endomycopsis ohmeri. It is hoped that the 
new International Botanical Congress-approved taxonomic changes mentioned above will 
allow the clinically important species to be known by their anamorph (Candida) names. 
However, the clinical community should be aware of multiple names for these organisms 
that may appear in the medical literature and should appreciate that, in many cases, these 
names all refer to a single organism.
Blastoschizomyces capitatus (Dipodascus capitatus) is an uncommon cause of disseminated 
disease in immunosuppressed individuals. An older name for this fungus is Geotrichum 
capitatum. Geotrichum candidum has its teleomorph in the genus Galactomyces as G. 
candidus. Although these two organisms are not closely genetically related, both produces 
arthroconidia and can be confused with Trichosporon species (see below).
Novel Species with Single Case Reports
Recently the novel species Candida aaseri and C. pseudoaaseri, which are close genetic 
relatives, have been recovered from human clinical samples. C. aaseri was isolated from 
sputum of a Norwegian patient and was not considered clinically relevant, but C. 
pseudoaaseri was recovered from blood in an immunocompromised cancer patient in 
Germany [21]. Both species produce a blue colony on ChromAgar Candida somewhat 
similar to that of C tropicalis, produce pseudohyphae but not chlamydospores on cornmeal 
agar, and require DNA sequencing to distinguish them, relying on variation in the ITS 
region. C. pseudoaaseri has low MICs to all classes of antifungal drugs except flucytosine, a 
feature that also distinguishes this species from C. aaseri, which is generally susceptible.
Candida subhashii was isolated from peritoneal fluid in a patient with end-stage renal failure 
and peritonitis [22]. The isolate was white on ChromAgar Candida and produced long 
Brandt and Lockhart Page 6









pseudohyphae on cornmeal agar. Identification was made by DNA sequencing, where the 
isolate was found to be genetically most closely related to the C. parapsilosis species 
complex, C. tropicalis, C. albicans, and C. dubliniensis. MIC testing found that it 
demonstrated low MICs to azoles and amphotericin B.
Candida auris was first reported from Japan and South Korea from external ear samples in 
patients with chronic otitis media. At the time, its clinical significance was unclear. In 2011, 
this species was detected in South Korea as an agent of bloodstream infection in three 
patients, all of whom had pre-existing clinical conditions and were receiving broad-spectrum 
antibiotics and parenteral nutrition [23]. The isolates were originally misidentified using 
phenotypic methods as either Candida haemulonii or Rhodotorula glutinis, and DNA 
sequencing was required to provide the final identification. This species showed a close 
relationship to Candida haemulonii when studied phylogenetically. The MIC to fluconazole 
was high (range 2 to 128 µg/mL), but all isolates had low MICs to echinocandin drugs. All 
patients demonstrated persistent fungemia (10–31 days) that ultimately resolved with 
catheter removal and replacement of fluconazole therapy with amphotericin B.
Basidiomycetous Yeast
Cryptococcus Species
The two major species causing human infection are Cryptococcus neoformans and 
Cryptococcus gattii. After historically recognizing them as the single species C. neoformans, 
a number of phylogenetic studies have now resulted in their designation as separate species 
[24]. Most commercial yeast identification systems as well as the common cryptococcal 
antigen test performed on blood and spinal fluid do not distinguish between the two species. 
CGB (glycine-canavanine-bromthymol blue) medium is now commercially available in the 
United States to separate isolates into the two species, relying on the ability of C. gattii 
strains to assimilate glycine in the presence of canavanine and turn the medium from green 
to cobalt blue. C. neoformans strains do not assimilate glycine and the medium remains 
green after two to five days of incubation [25]. A variety of molecular methods can also be 
used to separate the two species, including MLST (multilocus sequence typing) and AFLP 
(amplified fragment length polymorphism) [26•]. A consensus MLST scheme for subtyping 
cryptococcal strains has been published [27].
The species Cryptococcus neoformans comprises organisms of serotypes A (C. neoformans 
var. grubii), D (C. neoformans var. neoformans) and AD (aneuploid hybrid strains). They 
are best known as causes of pneumonia, fungemia and meningitis in individuals world-wide, 
primarily in HIV-infected hosts but also in organ transplant recipients and individuals taking 
TNF-inhibitors for treatment of rheumatoid arthritis. Serotype A is the most commonly 
isolated type worldwide. Serotype D is more geographically restricted, found mostly in 
Mediterranean Europe. Hybrids of serotypes A and D are occasionally found in human 
disease.
Cryptococcus gattii refers to serotype B and C organisms, and may also be a species 
complex [24, 28]. This species has been found in Africa causing fungemia and meningitis in 
HIV-infected individuals, with a clinical presentation indistinguishable from that of serotype 
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A disease. In the 1980s and 90s, cases of C. gattii were also reported in otherwise healthy 
individuals in Australia, as well as from Southern California and South America. In 1999, C. 
gattii appeared in Vancouver Island, Canada, causing disease in both humans and animals 
[reviewed in 29]. This disease was traced to a particular molecular type, VGII, which is 
genetically different from types found in Australia (mostly VGI). C. gattii has also surfaced 
in the northwestern United States (Washington, Oregon, Idaho, California). Outbreak strains 
(VGIIa, VGIIb, and VGIIc) differ from non-outbreak strains (VGI, VGIII, and VGIV) in 
clinical presentation and patient characteristics. Patients with outbreak strains were more 
likely than patients with non-outbreak strains to have pre-existing medical conditions and 
respiratory symptoms, and less likely to have central nervous system symptoms [30•]. In 
another study, fluconazole MIC values were found to be correlated with subtype. VGI and 
VGIII isolates had comparatively low MIC to fluconazole, while VGIIc isolates had high 
MICs (16–32 µg/mL) to this drug [31, 32]. It is not clear if these differences translate into 
variation in responsiveness of the C. gattii subtypes to fluconazole therapy.
A number of Cryptococcus species that are not C. neoformans or C. gattii have been 
implicated in human disease. It is difficult to evaluate such reports because in most cases the 
isolates were not confirmed using DNA sequencing or other molecular testing, so the 
possibility of misidentification was not always formally ruled out.
Trichosporon Species
Members of the genus Trichosporon are increasingly recognized as causes of serious human 
disease, as well as skin and hair infections. A recent review regards this genus as the second 
most important cause of disseminated yeast infections in immunosuppressed patient 
populations [33], but it may fall to third if both Cryptococcus and Candida are counted. 
Although 37 species of Trichosporon are considered valid at this writing, nearly all systemic 
human infections area caused by one of six species, including T. asahii, T. asteroides, T. 
cutaneum, T. inkin, T. mucoides, and T. ovoides. The former Trichosporon beigelii has been 
declared an invalid name and is no longer used. Some of the newly reported species include 
Trichosporon mycotoxinivorans, an agent causing pneumonia in a cystic fibrosis patient 
[34].
Although it is fairly straightforward to identify Trichosporon to the genus level using 
phenotypic features, members of Trichosporon can be confused with the genera 
Blastoschizomyces and Geotrichum when morphology alone is considered. It is important to 
appreciate that Trichosporon and Blastoschizomyces/Geotrichum can both display 
arthroconidia on morphology media. Urease is important in distinguishing Trichosporon 
(urease-positive) from Blastoschizomyces/Geotrichum (urease-negative). DNA sequencing 
is mandatory to identify the individual species of Trichosporon. The ribosomal IGS 
(intergenic spacer) region is the preferred region to target in distinguishing species from one 
another, as the ITS region does not have sufficient discriminatory power. In addition, nine T. 
asahii genotypes can be distinguished based on analysis of the IGS region [33].
Treatment of trichosporonosis remains challenging. Strains of various species resistant to 
amphotericin B, fluconazole, and itraconazole have been reported. Echinocandins are not 
recommended for treating Trichosporon infections due to low activity. Combination therapy 
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with amphotericin B and an azole drug may be the most reliable avenue for successful 
treatment.
Rhodotorula Species
Most clinically important members of this genus are either Rhodotorula mucilaginosa or 
Rhodotorula glutinis. These organisms are easily distinguished by their orange-pink color 
and lack of pseudohyphae. Rhodotorula is a normal inhabitant of moist skin and can be 
recovered from bathrooms, showers, and toothbrushes. It is an uncommon cause of 
meningitis, fungemia, endocarditis, and other systemic infections in immunocompromised 
patients. In a recent 12-year review of bloodstream infections at a referral cancer center, 21 
cases of Rhodotorula infections were reported [35]. Rhodotorula infections can be difficult 
to treat due to both azole and echinocandin resistance, but are generally responsive to 
amphotericin B.
Malassezia Species
The taxonomy of Malassezia remains a topic of much investigation. The Mycobank 
database lists 17 species at this writing. Malassezia species are considered part of the normal 
skin flora in humans and animals. They can cause superficial infection known as pityriasis 
versicolor as well as fungemia and other deep infections in infants and adults [36]. M. 
pachydermatis is the best recognized, probably because it can grow on fungal media without 
lipid supplementation.
Conclusions
Advances in identification and taxonomy of yeast have led to the recognition of many novel 
“cryptic species” or “species complexes” that are mostly refractory to the traditional 
phenotype-based identification methods commonly employed in clinical laboratories. 
Furthermore, continued increases in susceptible patients and the selection pressures imposed 
by antifungal drug use will continue to result in the appearance of novel organisms that may 
not be easily recognized in clinical laboratories. Precise naming of such agents will require 
the use of DNA or MALDI-based identification methods. DNA-based methods are preferred 
for identification of unknown agents because, although their DNA sequence will not match 
precisely any sequences in published databases, their closest genetic neighbors can be easily 
determined, facilitating their taxonomic placement. As such instrumentation becomes more 
affordable molecular methods will probably be used more and more frequently, especially in 
reference institutions and those serving large numbers of critically ill patients. However, at 
this time such precise levels of identification may not be required for most sporadic yeast 
isolates. Identification as “Candida X species complex” may become the norm. It will be 
important for clinicians to appreciate that identification at the species complex level may 
encompass multiple species, not all of which may share the same antifungal drug 
susceptibility profile.
The clinical value of routinely identifying and reporting cryptic species is not clear at this 
time. A major reason for precise species identification is the central role of species 
identification in predicting antifungal resistance for yeasts that have not been specifically 
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tested for susceptibility. With the adoption of species-specific MIC breakpoints, it will be 
mandatory to identify a given yeast isolate to species prior to reporting an MIC profile, so 
that the correct breakpoints can be applied. However, an association between species and 
antifungal susceptibility/resistance has not been fully delineated for many of the cryptic 
species. For example, Candida nivariensis has been noted as uniformly resistant to multiple 
azole drugs, but Candida bracarensis shows more variable susceptibility. It would probably 
be worthwhile to distinguish C. nivariensis from C. glabrata, but the value of routinely 
distinguishing C. bracarensis from C. nivariensis is less clear.
Finally, the end of “one fungus-two names” nomenclature rules will hopefully provide 
important clarity to the identification of fungal pathogens in the clinical laboratory, by 
allowing one name to be consistently used for human pathogenic yeasts. Further studies will 
be required to assess the epidemiology and significance of these taxonomic changes on 
clinical practice and patient management.
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Table 1
Anamorph, teleomorph and older names for selected human pathogenic yeast
Anamorph name Teleomorph name (if present) Older name
Blastoschizomyces capitatus Dipodascus capitatus Geotrichum capitatum
Candida ciferrii Trichomonoascus ciferrii Stephanoascus ciferrii
Candida famata Debaryomyces hansenii
Candida fermentati Meyerozyma caribbica Pichia caribbica
Candida guilliermondii Meyerozyma guilliermondii Pichia guilliermondii
Candida guilliermondii var. membranifaciens Kodamaea ohmeri Pichia ohmeri
Candida kefyr Kluyveromyces marxianus
Candida krusei Pichia kudriavzevii Issatchenkia orientalis
Candida lipolytica Yarrowia lipolytica
Candida lusitaniae Clavispora lusitaniae
Candida palmioleophila None
Candida pelliculosa Wickerhamomyces anomalus Pichia anomala
Hansenula anomala
Candida utilis Lindnera jadinii
Cryptococcus gattii Filobasidiella bacillispora Cryptococcus neoformans var. gattii
Cryptococcus neoformans Filobasidiella neoformans Cryptococcus neoformans var. grubii (serotype A) and C. 
neoformans var. neoformans (serotype D)
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